Cargando…
Results from the Children’s Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma
Autor principal: | Carcaboso, Angel M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644028/ https://www.ncbi.nlm.nih.gov/pubmed/37969125 http://dx.doi.org/10.21037/tp-23-388 |
Ejemplares similares
-
A monoclonal antibody specifically reactive with Ewing's sarcoma.
por: Hara, S., et al.
Publicado: (1989) -
First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma
por: Spasov, Neofit J., et al.
Publicado: (2022) -
Ewing-like sarcomas: New molecular diagnoses in need of optimized treatment approaches
por: Lee, Alex T.J., et al.
Publicado: (2019) -
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children’s Oncology Group
por: Shulman, David S., et al.
Publicado: (2022) -
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol
por: Anderton, Jennifer, et al.
Publicado: (2020)